Spots Global Cancer Trial Database for met poisitivity is defined as at least half of tumor cells show weak, moderate or high staining
Every month we try and update this database with for met poisitivity is defined as at least half of tumor cells show weak, moderate or high staining cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Pilot Study of Crizotinib in Patients With c-MET Positive Gastric Adenocarcinoma as a Third-line Chemotherapy | NCT02435108 | c-MET Positive ... | crizotinib | 20 Years - | Samsung Medical Center | |
| A Pilot Study of Crizotinib in Patients With c-MET Positive Gastric Adenocarcinoma as a Third-line Chemotherapy | NCT02435108 | c-MET Positive ... | crizotinib | 20 Years - | Samsung Medical Center | |
| A Pilot Study of Crizotinib in Patients With c-MET Positive Gastric Adenocarcinoma as a Third-line Chemotherapy | NCT02435108 | c-MET Positive ... | crizotinib | 20 Years - | Samsung Medical Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
